Multiple Myeloma

P2, N=76, Completed, University of Chicago | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026

P1, N=4, Terminated, Celgene | N=156 --> 4 | Active, not recruiting --> Terminated; Business objectives have changed

P=N/A, N=204, Not yet recruiting, First Affiliated Hospital Xi'an Jiaotong University

P=N/A, N=200, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Apr 2026 --> Apr 2028 | Trial primary completion date: Apr 2026 --> Apr 2028

P1/2, N=49, Active, not recruiting, Mayo Clinic | Trial completion date: May 2028 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Sep 2026

P1, N=12, Not yet recruiting, Peter MacCallum Cancer Centre, Australia

P=N/A, N=85, Not yet recruiting, University Hospital, Limoges

Daratumumab-mediated disruption of mitochondrial transfer reduced the mitochondrial content in MM cells, prevented the boost in OXPHOS, significantly impaired MM cell growth and migration, and mitigated drug-resistance. In conclusion, we reveal a crucial metabolic interplay between monocytes and MM cells within the BM microenvironment that promotes tumor growth and induces therapy resistance, providing the rationale for treatment strategies that combine targeting tumor metabolism with existing anti-MM agents.

We report a case of minimal change disease presenting with AKI and nephrotic-range proteinuria 3 weeks after B-cell maturation antigen-directed CAR-T cell therapy, ciltacabtagene autoleucel, in a patient with relapsed refractory multiple myeloma. The patient received one dose of rituximab along with a short course of corticosteroid and had complete kidney recovery by week 4 of therapy. This report emphasizes the need for further investigation into the mechanism of kidney toxicity following CAR-T cell therapy, and potential benefits and risks of immunosuppressive therapy in this context.

P2, N=45, Active, not recruiting, Nantes University Hospital | Recruiting --> Active, not recruiting

P1, N=24, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China

In our real-life study, we confirmed the strong negative impact of lenalidomide on PBSC collection by comparing lenalidomide-treated patients with a control cohort of thalidomide-treated subject, also showing a more frequent use of plerixafor to mitigate these effects, thereby reducing the reliance on cyclophosphamide, that was associated with lower risk of prolonged apheresis sessions. Indeed, we showed that lenalidomide use significantly impaired stem cell collection, with prolonged apheresis sessions and lower CD34+ cell collection on day 1, while post-transplant outcomes did not significantly differ between groups. Our real-life bi-center experience is of great interest in the era of daratumumab-based regimens as first-line therapy for autologous stem cell transplantation-eligible MM patients, because the concomitant use with lenalidomide might negatively affect PBSC mobilization, urging for more tailored PBSC collection strategies.